Quantbot Technologies LP Invests $1.44 Million in Charles River Laboratories International, Inc. $CRL

Key Points

• Quantbot Technologies LP bought a new stake of 9,215 shares in Charles River Laboratories in the third quarter, valued at about $1.44 million per its SEC filing.
• Analysts are mostly bullish on CRL — with 10 Buys, 5 Holds and 1 Sell and an average price target of $203.57 — including recent upgrades like Citigroup to $265 and Evercore to $260.
• Charles River beat quarterly EPS estimates ($2.39 vs. $2.33) and slightly beat revenue expectations ($994.2M vs. $987.0M) despite a 0.8% YoY revenue decline, and set FY2026 guidance of $10.70–$11.20 EPS.

Quantbot Technologies LP purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 9,215 shares of the medical research company's stock, valued at approximately $1,442,000.

A number of other institutional investors have also modified their holdings of CRL. Rothschild Investment LLC grew its position in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company's stock valued at $29,000 after acquiring an additional 84 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International during the second quarter worth approximately $29,000. Atlantic Union Bankshares Corp acquired a new stake in Charles River Laboratories International during the 3rd quarter worth $31,000. Geneos Wealth Management Inc. lifted its holdings in shares of Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company's stock valued at $44,000 after purchasing an additional 145 shares during the last quarter. Finally, Allworth Financial LP lifted its stake in Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company's stock valued at $45,000 after buying an additional 190 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Bank of America raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and set a $225.00 target price for the company in a report on Monday, December 15th. Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a research note on Monday, December 1st. Citigroup upped their price target on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a "buy" rating in a report on Friday, January 16th. Evercore raised their target price on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the company an "outperform" rating in a report on Tuesday, January 13th. Finally, Robert W. Baird set a $193.00 target price on Charles River Laboratories International in a report on Thursday, February 19th. Ten equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $203.57.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $181.54 on Friday. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $228.88. The firm has a market capitalization of $8.94 billion, a P/E ratio of -61.33, a PEG ratio of 3.07 and a beta of 1.64. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. The firm has a fifty day moving average of $195.88 and a 200-day moving average of $180.60.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, topping analysts' consensus estimates of $2.33 by $0.06. The company had revenue of $994.23 million for the quarter, compared to analysts' expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm's quarterly revenue was down .8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.